Sex differences in outcomes with transcatheter aortic valve replacement

Transcatheter aortic valve replacement (TAVR) has emerged as a new standard of care for treating patients with symptomatic aortic stenosis (AS) and inoperable status. It was approved by the US Food and Drug Administration (FDA) in November 2011 (1). Ten months later, TAVR was approved by the FDA for treatment of high-risk but operable status patients with AS. Since then, TAVR has rapidly been adopted in clinical practice for the treatment of symptomatic AS patients at high risk for surgery. However, it remains unclear and unresolved whether there are sex-related differences in outcomes for patients who undergo TAVR.